HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bladder selectivity of the novel β₃-agonist ritobegron (KUC-7483) explored by in vitro and in vivo studies in the rat.

Abstract
We performed in vitro and in vivo experiments to evaluate the pharmacological profile of ritobegron and its effects on the bladder in rats. β(3)-AR selectivity was assessed using CHO cells expressing various subtypes of the human β-adrenoceptor (AR). Effects on isolated organs were evaluated using the organ-bath method. Effects on intravesical pressure, heart rate, and mean blood pressure were evaluated in urethane-anesthetized rats. Ritobegron increased cAMP accumulation in a concentration-dependent manner in CHO cells expressing any one of three human β-AR, its selectivity for β(3)-AR being 301-fold and 32-fold higher versus β(1)-AR and β(2)-AR, respectively. Ritobegron decreased the resting tension of the isolated bladder in a concentration-dependent manner (EC(50), 7.7 × 10(-8) mol/L; maximal relaxation, 97.0 %), and the β(3)-AR antagonist SR58894A produced a parallel rightward-shift of this concentration-response curve without altering the maximal response [pK(B) value, 6.43]. Ritobegron concentration-dependently increased atrial rate and decreased myometrial contractions in vitro, and its selectivity for the bladder was 2,078-fold higher versus the atria and 14-fold higher versus the uterus. In vivo, ritobegron induced a dose-dependent decrease in intravesical pressure (ED(50) 0.4 mg/kg), without affecting heart rate and only slightly lowering mean blood pressure. Thus, ritobegron displayed potent and selective β(3)-AR agonistic activity toward transfected human β-AR and exhibited a high selectivity for the bladder versus other organs in rats. Moreover, it decreased intravesical pressure with minimal effects on the cardiovascular system in anesthetized rats. These results suggest that ritobegron shows promise as a potential agent for the treatment of overactive bladder.
AuthorsItaru Maruyama, Yoshiaki Goi, Satoshi Tatemichi, Kazuyasu Maruyama, Yuji Hoyano, Yoshinobu Yamazaki, Hiroshi Kusama
JournalNaunyn-Schmiedeberg's archives of pharmacology (Naunyn Schmiedebergs Arch Pharmacol) Vol. 385 Issue 8 Pg. 845-52 (Aug 2012) ISSN: 1432-1912 [Electronic] Germany
PMID22552730 (Publication Type: Journal Article)
Chemical References
  • Acetates
  • Adrenergic beta-3 Receptor Agonists
  • Adrenergic beta-3 Receptor Antagonists
  • Adrenergic beta-Agonists
  • Colforsin
  • Cyclic AMP
  • ritobegron ethyl
  • p-Hydroxyamphetamine
  • Isoproterenol
Topics
  • Acetates (pharmacology)
  • Adrenergic beta-3 Receptor Agonists (pharmacology)
  • Adrenergic beta-3 Receptor Antagonists (pharmacology)
  • Adrenergic beta-Agonists (pharmacology)
  • Animals
  • CHO Cells
  • Colforsin (pharmacology)
  • Cricetinae
  • Cricetulus
  • Cyclic AMP (metabolism)
  • Female
  • Heart Rate (drug effects)
  • Humans
  • In Vitro Techniques
  • Isoproterenol (pharmacology)
  • Male
  • Muscle Relaxation (drug effects)
  • Organ Specificity
  • Rats
  • Rats, Sprague-Dawley
  • Substrate Specificity
  • Urinary Bladder (drug effects)
  • Urinary Bladder, Overactive (drug therapy)
  • p-Hydroxyamphetamine (analogs & derivatives, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: